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EDITORIALPlasmalemma Vesicle Associated Protein Truncation Causes
Lethal Protein-Losing Enteropathy in Humansrotein-losing enteropathy (PLE) is a syndrome thatPfeatures excessive losses of serum proteins into
the gastrointestinal (GI) tract. PLE elicits hypo-
proteinemia, often leading to severe edema, ascites,
malnutrition, and fatality in affected infants. Although
PLE is thought to be induced by several pathologic
conditions, ranging from erosive or nonerosive GI dis-
orders to increased intestinal pressure,1 the genetic and
molecular ontogenesis of PLE remains unclear. Current
treatment comprises primarily supportive measures,
including dietary modiﬁcation and maintenance of
nutritional status. The mortality that accompanies PLE
would be greatly reduced if we understood the under-
lying causes and could effectively identify the affected
patients by screening.
Elkadri et al2 used whole exome sequencing to identify a
homozygous nonsense mutation in the plasmalemma
vesicle-associated protein (PLVAP) gene in an infant who
died from a severe PLE condition. This identiﬁed 1072C>T
mutation causes a premature stop codon that truncates 84
amino acids off PLVAP’s C terminus. Surprisingly, the pri-
mary pathologic defects were not found in the patient’s
intestinal epithelial cells but rather in the intestinal vascular
endothelial cells. This ﬁnding differs somewhat from most
cases of enteropathy that affect young children, including
microvillus inclusion disease3 and congenital tufting enter-
opathy.4 In these latter conditions, genetic abnormalities
cause cellular abnormalities that primarily affect the intes-
tinal epithelial structure and function. In contrast, the
PLVAP p.R358 patient reported in this study showed
virtually no histologic abnormality in the intestinal epithe-
lium. Rather, the ultrastructural analyses present evidence
supporting a collapse of the intestinal vascular endothelium,
probably caused by a lack of diaphragms in the fenestrae.
This structural abnormality is believed to impair the gate-
keeping function of endothelium, causing the leakage of
plasma proteins.
Remarkably, a similar phenotype has been described in
Plvap knockout mice, with additional vascular endothelium
defects in several organs.5 The phenotypic features of the
endothelium in the PLVAP p.R358 patient largely resemble
those of Plvap knockout mice at both ultrastructural and
biochemical levels, strongly supporting a critical involve-
ment of PLVAP in PLE pathogenesis. It thus becomes
possible to screen infants for this genetic mutation and to
prevent severe complications at an early stage of the dis-
ease. The recent promise of gene therapy6 makes targeted
correction of PLVAP mutations plausible in future to cure
affected patients.Cellular and Molecular Gastroenterology and Hepatology 2015;1:348–3This novel monogenic lethal defect discovered by Elkadri
and colleagues sheds fresh light on new focus points that
must be explored by future studies. In particular, it will be
interesting to examine the molecular basis of leaky fenes-
trated capillaries in the intestinal endothelial cells lacking
PLVAP. Moreover, PLVAP mutations may result in congenital
malformation in other tissues besides intestines. This study
holds the key to insight into the endothelial barrier function
and intestinal homeostasis. As we move into the era of
precision medicine, more studies extrapolating genetic
causes of GI and hepatic disorders are needed to guide the
effective identiﬁcation and treatment of patients. A combi-
nation of basic research and clinical investigation, as ﬁnely
exempliﬁed by this work, will help achieve improved patient
outcomes.RYOTARO SAKAMORI
Department of Gastroenterology and Hepatology
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